1421 ET - Hims & Hers Health has ample opportunities to grow its weight-loss offerings even after GLP-1 drugs are taken off the FDA's shortage list, TD Cowen analysts say in a research note after meeting with management. A key concern for the stock is how the weight-loss platform will grow in a world if Hims can no longer offer compounded GLP-1s, the analysts say. But management believes it can provide a variety of weight loss offerings, including oral medication, personalized dosages of compounded GLP-1s, branded GLP-1s and liraglutide, that will ultimately be more affordable than a traditional GLP-1 program, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
November 08, 2024 14:21 ET (19:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。